News

November

Nov.27, 2020 Release

Shionogi Announces Supplemental New Drug Application for XOFLUZA® in Japan for the Post-Exposure Prophylaxis of Influenza Virus Infection was Approved.

Nov.25, 2020 Release

Shionogi and Nagasaki University Entered into Strategic Research Collaboration for Antimalarial Drugs with The Kitasato Institute.

Nov.24, 2020 Release

Shionogi Announces FDA Approval of XOFLUZA® (Baloxavir Marboxil) for the prevention of Influenza following contact with an infected person

Nov.16, 2020 Release

Inauguration of a Research Consortium for the Automated and Digitalized Chemical Synthesis with the University of Cambridge and AstraZeneca.

Nov.09, 2020 Release

Shionogi Received “2020 Award for Excellence in Corporate Disclosure” for four Consecutive Year from the Securities Analysts Association of Japan (SAAJ)

Nov.04, 2020 Notice

Transcript for FY2020 2Q Financial Results

Nov.02, 2020 Notice

Presentation Material for FY2020 2Q Financial Results

Nov.02, 2020 Release

Shionogi Announces Positive Topline Results from Phase 2 Study of BPN14770, a Drug Candidate for the Treatment of Brain Disorders Associated with Cognitive and Memory Deficits, in Patients with Fragile X Syndrome

October

Oct.30, 2020 Release

Notice Regarding Acquisition of Own Shares (Acquisition of own shares pursuant to the provisions of Article 165, paragraph 2 of the Companies Act)

Oct.30, 2020 Notice

Financial Results for the Second Quarter of FY2020

Oct.30, 2020 Release

IVIVC Enhancer, a novel accessory for dissolution test to be launched

Oct.26, 2020 Release

SHIONOGI ADVOCATES INNOVATION IN ANTIBIOTIC DEVELOPMENT AND POLICY CHANGE TO ADDRESS THE GROWING THREAT OF ANTIMICROBIAL RESISTANCE

Oct.20, 2020 Release

SHIONOGI TO PRESENT NEW DATA ON FETROJA® (CEFIDEROCOL) AT IDWEEK 2020

Oct.14, 2020 Release

SHIONOGI ANNOUNCES PUBLICATION OF TWO STUDIES IN THE LANCET INFECTIOUS DISEASES HIGHLIGHTING THE EFFICACY AND SAFETY OF CEFIDEROCOL FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE BACTERIA IN ADULTS WITH LIMITED TREATMENT OPTIONS

Oct.13, 2020 Notice

Establishment of the Joint Ventures between Shionogi and Ping An Group, “Ping An-Shionogi”,and Business Plan of Ping An-Shionogi

September

Sep.30, 2020 Release

Shionogi and HanaVax Enter into a License Agreement for Streptcoccus Pneumoniae Vaccine Candidate

Sep.29, 2020 Release

SHIONOGI ANNOUNCES FDA APPROVAL OF FETROJA® (CEFIDEROCOL) FOR THE TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA

Sep.24, 2020 Release

Shionogi Announces Commitment to Fight COVID-19 (5)

Sep.04, 2020 Release

SHIONOGI GRANTED NEW TECHNOLOGY ADD-ON PAYMENT FOR FETROJA® (CEFIDEROCOL) BY CMS Add-on Payment to Reimburse Hospitals up to 75 Percent of the cost of FETROJA in Hospital Inpatient Setting

August

Sep.01, 2020 Release

Shionogi to Announce Personnel Reassignment

Aug.31, 2020 Release

Shionogi Pharma to acquire Nagase Medicals as a wholly owned subsidiary

Aug.07, 2020 Release

Shionogi Announces Commitment to Fight COVID-19 (4)

Aug.07, 2020 Release

Shionogi to Announce Personnel Reassignment

Aug.03, 2020 Notice

Transcript of 1st Quarter of Fiscal 2020 Financial Results Conference Call

July

Jul.31, 2020 Notice

Presentation Material for FY2020 First Quarter Conference call

Jul.31, 2020 Notice

Financial Results for the First Quarter of FY2020

Jul.27, 2020 Release

Notice Regarding the Execution of the Agreements on
the Establishment of the Joint Ventures with Ping An and the Disposal of Treasury Shares by Way of Third-Party Allotment

Jul.22, 2020 Release

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Jul.13, 2020 Release

Shionogi Announces Corporate Reorganization and Personnel Reassignment

Jul.13, 2020 Release

Notice Regarding the Signing of the Agreements on the Establishment of the Joint Ventures with Ping An Insurance, the Establishment of a New Subsidiary, the Signing of the Agreements on Transfer of Subsidiary Shares and Equity Stakes, and the Disposal of Treasury Shares by Way of Third-Party Allotment

Jul.10, 2020 Release

New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion
- Partnership aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term policy solutions -

Jul.09, 2020 Release

Shionogi Included in Stock Indices (Index) for ESG Investing: FTSE4Good Index Series and FTSE Blossom Japan Index
- Shionogi Has Become the Constituent of the All Four Indices Used by Japan's Government Pension Investment Fund (GPIF) -

Jul.09, 2020 Release

BLOCKSTONE Study of Xofluza® (Baloxavir Marboxil) for the Prevention of Influenza in Household Contacts Published in The New England Journal of Medicine

June

Jun.30, 2020 Release

Signing of a new contract with StemRIM
- Toward Investigator-initiated Clinical Study Implementation of S-005151 [Generic Name: Redasemtide] -

Jun.23, 2020 Release

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Jun.22, 2020 Release

Business Partnership with Nihon University, Gunma University, and Tokyo Medical University for a Rapid Diagnostic Methods for Viruses in the Field of Infectious Diseases, Including Novel Coronavirus
- A Rapid Diagnostic Method with High Sensitivity that can be Visually Determined without the Need for a Detection Device in 25 Minutes of Reaction from Samples such as Saliva -

Jun.19, 2020 Release

Shionogi Announces Commitment to Fight COVID-19 (3)

Jun.09, 2020 Release

CAPSTONE-2 study of Xofluza® (Baloxavir Marboxil) for the Treatment of Influenza Published in The Lancet Infectious Diseases

Jun.03, 2020 Release

Shionogi Announces Commitment to Fight COVID-19 (2)

Jun.03, 2020 Release

IgG/IgM Antibody-test Kit for COVID-19 launched in Japan

Jun.02, 2020 Release

FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jun.01, 2020 Release

Notice Regarding a New Medium-Term Business Plan

May.29, 2020 Notice

Presentation Material for 2030 vision and Medium-Term Business Plan "Shionogi Transformation Strategy (STS2030)"

May

May.26, 2020 Release

Notice Regarding Tetra becoming a wholly owned subsidiary of Shionogi

May.25, 2020 Notice

“Notice of Convocation of the 155th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 155th Annual General Meeting of Shareholders”Open in a new tab

May.12, 2020 Notice

Presentation Material for FY2019 Financial Results

May.11, 2020 Notice

Financial Results for FY2019

April

Apr.28, 2020 Release

SHIONOGI RECEIVES EUROPEAN COMMISSION MARKETING AUTHORISATION FOR FETCROJA® (CEFIDEROCOL) FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE BACTERIA IN ADULTS WITH LIMITED TREATMENT OPTIONS

Apr.27, 2020 Release

Notice Regarding a Development Decision of Vaccine for COVID-19

Apr.24, 2020 Release

Notice of Revisions to Dividend Forecasts (Divident Increase)

Apr.22, 2020 Release

Position and Policy Regarding Reduction of the Investment Unit

Apr.14, 2020 Release

Shionogi Announces Commitment to Fight COVID-19

Apr.07, 2020 Release

Shionogi Issues the Shionogi Group Smoke-Free Declaration with the Aim of Achieving a Zero Smoking Rate among Its Employees

Apr.07, 2020 Release

Notice Regarding Completion of Cancellation of Treasury Shares(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)

Apr.01, 2020 Release

A New Maternal and Child Healthcare Program Kicks Off in Kilifi County, Kenya The Mother to Mother SHIONOGI Project Enters Its Second Phase with the Aim of Improving Health Access

March

Mar.31, 2020 Release

Shionogi Filed for the Supplemental New Drug Application of Xofluza® in Taiwan for the Post-Exposure Prophylaxis of Influenza Virus Infection

Mar.31, 2020 Release

Shionogi Joins The Valuable 500, an International Initiative for Promoting Disability Inclusion

Mar.31, 2020 Notice

Press Conference

Mar.30, 2020 Release

Notice Regarding the Signing of the Basic Agreement with Ping An Insurance for a Capital and Business Alliance including the Disposal of Treasury Shares by Way of Third-Party Allotment

Mar.30, 2020 Release

Notice Regarding Changes of Cancellation of Treasury Shares（Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act）

Mar.27, 2020 Release

FDA Accepts a New Drug Application for a New Formulation and Two Supplemental New Drug Applications for XOFLUZA® (Baloxavir Marboxil)

Mar.26, 2020 Notice

Transcript of the R&D Meeting

Mar.19, 2020 Notice

R&D Meeting

Mar.17, 2020 Release

Business Partnership with Micro Blood Science Inc. for an IgG/IgM Antibody-test Kit for COVID-19

Mar.10, 2020 Release

Partnership Agreement between Yabu City, Hyogo, and Shionogi on the Improvement of Community Healthcare

Mar.09, 2020 Release

Notice Regarding the Status and Completion of Acquisition of Own Shares(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Mar.06, 2020 Release

Shionogi Certified as Health and Productivity Management Organization 2020 for Fourth Consecutive Year

Mar.06, 2020 Release

Shionogi and Tetra Therapeutics Entered into New Strategic Collaboration for BPN14770, the Drug Candidates for the Treatment of Brain Disorders Marked by Cognitive and Memory Deficits

Mar.03, 2020 Release

Shionogi Receives Grand Prize Company Award for Corporate Governance of the Year 2019

Mar.03, 2020 Release

SHIONOGI RECEIVES POSITIVE CHMP OPINION FOR FETCROJA® (CEFIDEROCOL) FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE BACTERIA IN ADULT PATIENTS WITH LIMITED TREATMENT OPTIONS

February

Feb.25, 2020 Release

SHIONOGI to Announce Executive Appointments, Corporate Reorganization and Personnel Reassignment

Feb.25, 2020 Release

Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S.

Feb.07, 2020 Release

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Feb.04, 2020 Release

Shionogi Gains High Rating in Survey by CDP- Rated A- for “Climate Change” and Chosen as an A-List Company for “Water security” -

Feb.03, 2020 Notice

Financial Results for the Third Quarter of FY2019

January

Jan.08, 2020 Release

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)